在化疗领域的研究中,近来已向寻找具有抗菌活性增强、选择性增高的研究发展,要求这些化合物在维持抗菌效能的同时,且有安全性更高、使用方便、毒副反应发生率较低的特点。由于对第三代青霉素类和第三代头孢菌素类的开发,上述研究宗旨首先在β-内酰胺类领域内部份实现。然而,在其它抗生素类的研究领域中如氨基糖苷类,所获得的研究成果却不能令人满意。在此之前,在氨基糖苷类的研究开发中,寻找的高效低毒抗生素与已出现的β-内酰胺类相比尚无任何显著进展。直至Dactimicin的发现,才打开了氨基糖苷类研究领域的新局面。迄今为止,通过实验证明这种新抗生素Dactimicin不仅具有高度的抗菌活性,而且更重要的是具有毒性低和耐受性较强的特 In the field of chemotherapy, research has recently been looking for enhanced and selective antimicrobial activity, requiring that these compounds maintain antibacterial efficacy with higher safety, ease of use, and lower incidence of toxic and side effects specialty. Due to the development of the third generation of penicillins and third generation cephalosporins, the above aims of the study were first achieved partly in the field of β-lactams. However, the research results obtained by other antibiotics such as aminoglycosides are unsatisfactory. Prior to this, in the research and development of aminoglycosides, the search for high efficiency and low toxicity antibiotics has no significant progress compared with the existing β-lactams. Until the discovery of Dactimicin, opened up a new situation in the field of aminoglycosides research. So far, it has been experimentally demonstrated that this new antibiotic, Dactimicin, not only has a high degree of antibacterial activity, but more importantly, has low toxicity and high tolerance